Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Adlercreutzia equolifaciens Is an Anti-inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease

Florian Plaza-Onate
† ,
Célia Chamignon
† ,
Sebastian Burz
† ORCID logo ,
Nicolas Lapaque
,
Magali Monnoye
,
Catherine Philippe
,
Maxime Bredel
,
Laurent Chêne
,
William Farin
,
Jean-Michel Paillarse
,
Jérome Boursier
,
Vlad Ratziu
,
Pierre-Yves Mousset
,
Joël Doré
,
Philippe Gérard
ORCID logo ,
Hervé M. Blottière
* ORCID logo
†
These authors contributed equally to this work.
Version 1 : Received: 29 May 2023 / Approved: 30 May 2023 / Online: 30 May 2023 (08:59:14 CEST)

A peer-reviewed article of this Preprint also exists.

Oñate, F.P.; Chamignon, C.; Burz, S.D.; Lapaque, N.; Monnoye, M.; Philippe, C.; Bredel, M.; Chêne, L.; Farin, W.; Paillarse, J.-M.; Boursier, J.; Ratziu, V.; Mousset, P.-Y.; Doré, J.; Gérard, P.; Blottière, H.M. Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease. Int. J. Mol. Sci. 2023, 24, 12232. Oñate, F.P.; Chamignon, C.; Burz, S.D.; Lapaque, N.; Monnoye, M.; Philippe, C.; Bredel, M.; Chêne, L.; Farin, W.; Paillarse, J.-M.; Boursier, J.; Ratziu, V.; Mousset, P.-Y.; Doré, J.; Gérard, P.; Blottière, H.M. Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease. Int. J. Mol. Sci. 2023, 24, 12232.

Abstract

Non-alcoholic fatty liver disease (NAFLD) affects about 20–40% of the adult population in high-income countries and is now a leading indication for liver transplantation and can drive to hepatocellular carcinoma. The link between gut microbiota dysbiosis and NAFLD is now clearly established. Through analyses of the gut microbiota with shotgun metagenomics, we observed that compared to healthy controls, Adlercreutzia equolifaciens is depleted in patients with liver diseases such as NAFLD. Its abundance also decreases as the disease progresses and eventually disappears in the last stages indicating a strong association with disease severity. Moreover, we show that A. equolifaciens possesses anti-inflammatory properties, both in vitro and in vivo in a humanized mouse model of NAFLD. Therefore, our results demonstrate a link between NAFLD and the severity of liver disease and the presence of A. equolifaciens and its anti-inflammatory actions. Counterbalancing dysbiosis with this bacterium may be a promising live biotherapeutic strategy of liver diseases..

Keywords

NAFLD; Gut Microbiota; Inflammation; Metagenomics; Live Biotherapeutic Product

Subject

Medicine and Pharmacology, Gastroenterology and Hepatology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.